Podbit · The Peter Attia Drive
The brain's glymphatic waste-clearance system — which flushes amyloid and tau during deep sleep — roughly doubles its clearance rate during slow-wave sleep. DORAs preserve that architecture, and a 2023 human trial found 20 mg of suvorexant reduced CSF amyloid-beta by about 20%. The data are early but the signal is strong enough to warrant close attention.
Where this was said
At 28:40 · chapter starts 27:15
During slow-wave sleep, the brain's glymphatic system activates — neurons shrink slightly, opening about 60% more interstitial space, allowing CSF to circulate freely and carry away metabolic toxins including beta-amyloid and aberrant tau proteins implicated in Alzheimer's disease. Animal studies show glymphatic amyloid clearance roughly doubles during sleep, especially deep slow-wave sleep. Human studies confirm that even a single night of sleep deprivation impairs this clearance, and chronic disruption correlates with long-term amyloid and tau burden. The accumulation of these proteins in turn damages the brain regions that regulate sleep, creating a vicious cycle. Researcher David Holtzman suspected an orexin-amyloid link, since both orexin levels and CSF amyloid follow similar diurnal rhythms. His group infused orexin into mouse hippocampi and found it raised interstitial amyloid; the early DORA almorexant lowered it. Dayvigo in tau-mutant mice slowed tau pathology and brain atrophy in male mice. In a landmark 2023 human trial of 38 adults aged 45–65, 20 mg of Belsomra — but not 10 mg — reduced CSF amyloid-beta by ~20%. Ambien had no such effect. This specificity is critical: simple unconsciousness isn't doing the clearing. Three new clinical trials — two with ~200 subjects each — are underway and expected to report between now and 2029.
DORAs work by dialing down the brain's orexin-driven wakefulness system rather than forcing sedation — a fundamentally different mechanism that preserves sleep architecture and even improves REM sleep. Meta-analyses show superior sleep efficiency and tolerability compared to older drug classes.
During sleep, neurons shrink slightly, opening about 60% more interstitial space, allowing the glymphatic system to flush beta-amyloid and tau proteins from the brain.
Animal studies show glymphatic clearance of beta-amyloid roughly doubles during sleep, particularly during deep non-REM slow-wave sleep.
In a 2023 human trial, 20 mg of suvorexant (Belsomra) decreased CSF amyloid-beta by roughly 20% starting about 5 hours after administration.
Melatonin doesn't knock you out — it tells your brain what time it is. The optimal dose to shorten sleep latency is just 4 mg, yet most people take 5–10 mg, which can backfire by disrupting circadian alignment. And commercial product accuracy is so poor that actual content can range from 80% below to nearly 500% above the label claim.
Social norms compress behavior so effectively that we assume other minds are similar to ours. They almost never are. After running over 100 psychology studies, Greenberg's biggest finding is that humans are far more different from each other than we intuitively believe.
The widely shared claim that we have a credit card's worth of plastic in our brains may be a massive overestimate. Researchers used nitrile gloves to measure microplastics — and nitrile gloves shed microplastic particles onto the measuring device. A second paper found the original tool used was unreliable, and that we may have far less plastic than reported.
RSD isn't just hurt feelings — it's a dopamine-deficient brain with a hyperactive amygdala and a frayed connection to the prefrontal cortex. Add a surge of norepinephrine and you get chest pain, sweating, and trembling that convinces your body something catastrophic is happening.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.